Expanded parameters in active surveillance for low-risk papillary thyroid carcinoma: a nonrandomized controlled trial

AS Ho, S Kim, C Zalt, ML Melany, IE Chen… - JAMA …, 2022 - jamanetwork.com
Importance Unlike for prostate cancer, active surveillance for thyroid cancer has not
achieved wide adoption. The parameters by which this approach is feasible are also not well …
被引用次数：45 相关文章
[HTML] nih.gov

[HTML][HTML] Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial

AS Ho, S Kim, C Zalt, ML Melany, IE Chen… - JAMA …, 2022 - ncbi.nlm.nih.gov
Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial

AS Ho, S Kim, C Zalt, ML Melany, IE Chen… - JAMA … - pubmed.ncbi.nlm.nih.gov
Importance Unlike for prostate cancer, active surveillance for thyroid cancer has not
achieved wide adoption. The parameters by which this approach is feasible are also not well …

Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial.

AS Ho, S Kim, C Zalt, ML Melany, IE Chen… - JAMA …, 2022 - europepmc.org
Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A
Nonrandomized Controlled Trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A Nonrandomized Controlled Trial.

AS Ho, S Kim, C Zalt, ML Melany, IE Chen… - JAMA …, 2022 - europepmc.org
Expanded Parameters in Active Surveillance for Low-risk Papillary Thyroid Carcinoma: A
Nonrandomized Controlled Trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …